Altanispac Labs
Data-driven development.
Unparalleled ocular surface experience.
Altanispac Labs is a clinical-stage biopharmaceutical company advancing differentiated therapies for dry eye and corneal disease through disciplined development and real-world clinical expertise.
About Us
Altanispac is led by scientific and business leaders who have played central roles in the development, regulatory approval, and commercialization of many of today’s marketed dry eye and anterior segment therapies.
This experience, combined with a data-driven approach, informs every development decision — from product selection and clinical trial design through regulatory strategy and product positioning.
Our goal is to deliver truly differentiated therapies through comfortable, patient-friendly products with powerful biological activity that intervenes in the key processes responsible for maintaining ocular surface homeostasis.
Advancing new standards of care
in dry eye & ocular surface disease
Dry eye disease is a complex, multifactorial condition that affects millions of patients worldwide. Despite multiple approved therapies, many patients continue to experience inadequate relief, limited tolerability, or inconsistent long-term benefit.
Altanispac Labs applies a more informed, experience-driven approach to addressing these unmet needs across dry eye and related ocular surface conditions.
Our Difference
The Altanispac team brings deep, firsthand experience across the full lifecycle of anterior segment and dry eye therapy development.
Our leaders have played central roles in the development, regulatory approval, and commercialization of many of today’s marketed dry eye products, giving us a practical understanding of what drives real differentiation and long-term success.
This depth of experience provides a practical understanding of successful clinical pathways and where meaningful differentiation still exists. We are data-driven at every level, using translational insight and clinical evidence to guide decision-making.
Patient-centered by design
The patient experience is not an afterthought. It is the product.
Patients with dry eye and ocular surface disease need more than modest symptom relief.
They need:
-
A comfortable drop they can use consistently
-
Powerful biological activity that addresses the underlying disease
-
Meaningful, sustained improvement in daily life
Above all, our approach is informed by all aspects of the patient experience and how it can better inform advancements in product development.
Science & Mechanism
Matching disease biology with precise drug activity.
Our approach integrates:
-
A thoughtful understanding of dry eye pathophysiology
-
Targeted intervention in the key biological processes that maintain ocular surface homeostasis
-
Clinical trial designs optimized to demonstrate true differentiation and facilitate market access
-
Operational oversight informed by decades of first-hand clinical development experience experience
Mechanism, trial design, and regulatory strategies are developed in unison, ensuring alignment for future commercialization.
Our Development Philosophy
Disciplined. Focused. Experienced.
We advance programs with:
• Clear mechanistic rationale
• Translational markers that inform development decisions
• Endpoints that matter to patients, clinicians, regulators and payors
• Efficient, capital-conscious execution
We are creative, efficient, and targeted in our approach.
Partnerships
Built to collaborate. Structured to deliver.
Altanispac Labs actively engages with strategic partners who value:
• Deep ocular surface and anterior segment expertise
• Data-driven development
• Transparent collaboration
• Clear economic alignment
We welcome discussions with pharmaceutical partners, investors, and collaborators aligned with our mission.